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Quetiapine is occasionally associated with cardiovascular adverse eﬀects such as QTc prolongation. QTc prolongation is a side
eﬀect that requires monitoring in order to avoid more serious cardiac complications. One particular understudied area is the
potential for antipsychotics to elicit electroconduction abnormalities in patients with Wolﬀ-Parkinson-White (WPW)
Syndrome. In the present report, we describe a case of quetiapine overdose in a patient with WPW.

1. Introduction

2. Case Report

Wolﬀ-Parkinson-White (WPW) Syndrome is a cardiac condition deviation characterized by an accessory pathway that
bypasses the atrioventricular (AV) node resulting in abnormally fast ventricular contractions. Speciﬁc electrocardiogram (EKG) ﬁndings of WPW include delta wave, widened
QRS complex (>110 ms), shortened PR interval (<120 ms),
and inverted T waves [1]. Although generally asymptomatic
[2], the most common clinical symptom is “palpitations of
the heart [3].” In rare, severe cases, WPW has been linked
to Torsades de pointes and sudden cardiac death [4]. While
the pathophysiology of WPW is well established and studied,
the eﬀects of antipsychotics on patients with WPW remain
unknown.
Other cardiac consequences of antipsychotic medications
have been well characterized, including QTc prolongation
[5]. Speciﬁcally, quetiapine is well known to have QTc
prolonging eﬀects and has been linked to dangerous conditions such as Torsades de pointes [6]. However, the potential
eﬀects of quetiapine on patients with WPW have not been
described. Therefore, here, we report the consequences of a
quetiapine overdose in a patient with WPW.

A 30-year-old female with a past medical history signiﬁcant
for WPW and a psychiatric history of major depressive disorder, posttraumatic stress disorder, borderline personality disorder, and several suicide attempts presented to the
Emergency Department (ED) with complaints of decreased
energy, swollen lymph nodes, weight loss (approximately
13.5 kg), and mild abdominal pain. Subsequent interviews
revealed that while waiting for the results of her evaluation,
the patient overdosed on 1200 mg of trazodone, 1200 mg of
quetiapine, and 900 mg of venlafaxine, as a suicide attempt.
Two hours postoverdose, the patient began to exhibit a prolonged QTc interval of 486 ms which contrasted with her
QTc baseline of 445 ms (Figure 1). Of note, no delta wave
was appreciated in the EKG. Her PR interval was 160 ms at
baseline and 146 ms 2 hrs after (Table 1). Baseline blood pressure was noted at 114/70, but 2 hours postoverdose, the
patient developed hypotension of 86/45 mmHg. In addition,
the patient complained of palpitations with a heart rate ranging from 83 to 97. All psychiatric medications were discontinued, and intravenous ﬂuids were provided. Forty-eight
hours after discontinuation of her medication, the patient’s

2

Case Reports in Psychiatry
500

Time (ms)

450

400

350

300
Base

2-hour

24-hour

48-hour

1-year

Figure 1: Eﬀects of quetiapine on QTc on a patient with Wolﬀ-Parkinson-White (WPW) Syndrome. This graph represents changes in the
QTc interval expressed in milliseconds at various points in time including at baseline, 2, 24, and 48 hours postoverdose and then ﬁnally a
year after.
Table 1: EKG parameters at baseline and several time points after
quetiapine overdose.

Baseline
2-hour postintoxication
24-hour postintoxication
48-hour postintoxication
1-year postintoxication

QT

QTc

PR interval

Pulse

358 ms
416 ms
404 ms
414 ms
344 ms

445 ms
486 ms
472 ms
434 ms
450 ms

160 ms
146 ms
180 ms
160 ms
170 ms

93 BPM
82 BPM
82 BPM
66 BPM
89 BPM

EKG normalized including her QTc interval (QT/QTc of
414/434) (Figure 1), and her PR interval was at 160 ms
(Table 1). At this point, the patient was medically cleared
and transferred to our inpatient unit.
On the inpatient unit, the patient was slowly reintroduced to her psychiatric medications. On day 1, the patient
was started on quetiapine 100 mg at bedtime, trazodone
100 mg at bedtime, and venlafaxine 150 mg in the morning.
This was gradually raised to a maximum dose of quetiapine100 mg in am and 300 mg at bedtime. Venlafaxine was
increased to 225 mg daily and trazodone remained at
100 mg at bedtime. Apart from mild sedation, the patient
reported no symptoms or side eﬀects from medications such
as sensation of rapid, ﬂuttering, or pounding heartbeats (palpitations); dizziness or lightheadedness; or shortness of
breath. The patient was discharged after 11 days of inpatient
psychiatric treatment.
After discharge, maintenance treatment consisted of
300 mg of quetiapine, 100 mg of trazodone, and 225 mg of
venlafaxine. A year later, the patient was seen in the ED for
chest palpitations, pain, and dizziness. Her initial EKG was
signiﬁcant for heart rate of 109 beats per minute, QTc of
450 ms, and PR interval of 160 ms. Twenty-four hours later
her EKG showed a QTc interval of 457 ms, PR interval of
170 ms, and heart rate of 89 bpm (Figure 1). Of note, delta
waves were not appreciated on either EKG. Initially, the
patient was worked up for chest pain via 3 sets of troponins,
EKG, and stress test. All test results came back negative. Her
symptoms resolved within 24 hours with no changes in med-

ication, and the patient was discharged without further
issues.

3. Discussion
In recent years, special consideration has been placed on the
QTc prolonging side eﬀects of various psychotropic medications, particularly, typical antipsychotics such as haloperidol
[7], droperidol [8], and atypical antipsychotics such as olanzapine, ziprasidone, and risperidone [9]. But very little is
known about the eﬀects antipsychotics may have on patients
with WPW. We have recently reviewed all published information currently available [10], which mostly comes from
case reports, some providing conﬂicting results. For example,
olanzapine has been shown to have varying levels of safety in
WPW patients. In one case a dosage of 5 mg/day was shown
to cause QTc prolongation from 390 to 466 ms [11]. In
another case, a dosage of 7.5 mg/day was shown to have no
eﬀect on QTc intervals [12]. On the other hand, data on risperidone is more consistent. In two separate cases, risperidone at 1 mg BID induced palpitations, QTc prolongation,
shortened PR intervals, and induction of a delta wave on
EKG [9, 13]. To our knowledge, there is no published data
on the eﬀects of quetiapine on WPW.
Quetiapine is a dibenzothiazepine derivative that is FDAapproved to treat schizophrenia and bipolar disorder. Compared to typical antipsychotics, quetiapine is unique in that
it has transient antagonist eﬀects on dopamine 2 receptors
and, as a result, lower risk for extrapyramidal symptoms
[14]. At the same time, when compared to typical antipsychotics, quetiapine has an aﬃnity for muscarinic receptors
resulting in anticholinergic side eﬀects such as orthostatic
hypotension and transient sedation [15].
The general medical eﬀects of quetiapine overdose have
been documented in several previous case studies. Most overdose cases result in exaggeration of the anticholinergic side
eﬀects including tachycardia, hypotension, and sedation.
However, several other symptoms have been documented
in severe overdoses. One report in a 26-year-old woman
who ingested over 10,000 mg of quetiapine, resulted in rapid
deterioration of mental status and required intubation [16].
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Another case was a 19-year-old man who ingested 9,600 mg
of quetiapine, leading to QTc prolongation [17]. A third publication described a 31-year-old female who ingested
2,000 mg of quetiapine and then became comatose requiring
intubation. QTc prolongation was also observed [5].
In our case, our patient had an overdose of 1,200 mg that
resulted in typical anticholinergic side eﬀects of hypotension
and sedation. Initially, the patient presented with concerning
symptoms of QTc prolongation. However, despite having an
extra electrical pathway, the patient did not develop any
further cardiac complications such as arrhythmia. In fact,
discontinuation of quetiapine led to recovery within 48
hours. Furthermore, after reintroduction of quetiapine to
therapeutic levels, the patient did not present any clinical
symptoms associated with WPW such as palpitations or
shortness of breath. The only symptoms that the patient
expressed were mild fatigue, which can be attributed to
the anticholinergic eﬀects of quetiapine and mild QTc prolongation. Of note, the side eﬀect of fatigue resolved after
slightly lowering her quetiapine dose. Her QT interval also
returned to baseline.
Most importantly, the patient was discharged on a therapeutic dose of quetiapine with no cardiac complications. This
was conﬁrmed upon reevaluation 1 year after discharge in
which the patient initially reported some symptoms that
could be related to WPW. While the patient did report palpitations, the EKG demonstrated a QTc interval similar to
baseline. A repeat EKG 24 hours later remained at baseline.
Thus, it is evident that 1 year of therapeutic dosage of quetiapine did not aﬀect the patient’s WPW.
It also has to be considered that the patient was concomitantly taking trazodone and venlafaxine. While some studies
have shown a slight increase in QTc interval with trazodone
[18] and venlafaxine [19], this side eﬀect is less frequently
observed than when quetiapine is administered. The combination of quetiapine with trazodone, especially considering
that the patient overdosed on 2000 mg of trazodone, could
have elicited signiﬁcant QTc prolongation and even Torsades. Serious cardiac arrhythmias have been documented
in cases of trazodone and venlafaxine overdose or when combined with other QTc prolonging medications [20].
In conclusion, to our knowledge, this is the ﬁrst case
reporting the potential eﬀects of quetiapine, trazodone, and
venlafaxine in an individual with WPW, and no serious cardiac complications were encountered even after a year of
follow-up. But these medications cannot be considered
entirely safe for patients with WPW until further research
is developed on this topic.
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